1 / 17

NHS Community Pharmacy Contractual Framework

NHS Community Pharmacy Contractual Framework. A summary of service developments in 2011/12. Overview of presentation. Changes to the MUR service Changes to clinical governance New Medicine Service (NMS) Implementation timetable. Community Pharmacy’s Contribution to the NHS.

spike
Download Presentation

NHS Community Pharmacy Contractual Framework

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NHS Community Pharmacy Contractual Framework A summary of service developments in 2011/12

  2. Overview of presentation • Changes to the MUR service • Changes to clinical governance • New Medicine Service (NMS) • Implementation timetable

  3. Community Pharmacy’s Contribution to the NHS • PSNC and NHS Employers believe the introduction of these changes will: • Lead to improved outcomes for patients and deliver a better patient experience • Support better use of community pharmacy expertise • Provide value for money for the NHS and lead to better use of resources • Contribute to the NHS Quality, Innovation, Productivity and Prevention (QIPP) programme

  4. Changes to the MUR service • Changes are intended to help demonstrate the benefits of the service to patients and the NHS • Introduction of national target groups • patients taking high risk medicines (on a national list) • patients recently discharged from hospital who had changes made to their medicines while they were in hospital • patients with respiratory disease

  5. Changes to the MUR service • Further target groups will be identified • At least 70% of all MURs should be on patients within the national target groups • MURs should be conducted on patients who are on more than one prescribed medicine • Outcome measures will be developed prior to implementation of these changes

  6. Changes to the MUR service • Consent arrangements for MURs will be updated • Next steps for PSNC and NHS Employers • Stakeholder input on additional target groups and outcome measures • Develop guidance for contractors and PCTs

  7. Changes to clinical governance • Changes aim to strengthen and build upon the existing clinical governance regime • The changes: • Acknowledgment of NHS funding when advertising services • A requirement to reflect on the results of the CPPQ, take appropriate action and publish the results

  8. Changes to clinical governance • Patient safety incident and near-miss logs must be kept and reports made to NRLS • Whistle blowing policy • MHRA, NPSA and DH alerts should be actioned within required timescales and a record kept of actions undertaken • Cleanliness and infection control measures proportionate to the activities being undertaken in the pharmacy

  9. Changes to clinical governance • Premises should provide a professional healthcare environment • Next steps for PSNC and NHS Employers • Develop guidance for contractors and PCTs • Provide examples of best practice

  10. New Medicine Service • Based on proof of concept research • Advanced service (time limited to March 2013) • Service will continue if it has demonstrated value to the NHS • As part of the implementation programme we will work with appropriate expert stakeholders to confirm the knowledge and skills pharmacists require to deliver NMS

  11. New Medicine Service • Funding • Up to £55m in both 2011/12 and 2012/13 • 2011/12 – implementation payment and target payments • 2012/13 – target payments • Target payments will depend on the achievement of activity thresholds which will be related to the prescription volume

  12. New Medicine Service • PSNC and NHS Employers envisage that the successful implementation of NMS will: • improve patient adherence • increase patient engagement with their condition and medicines • reduce medicines wastage • reduce hospital admissions due to adverse events from medicines • lead to increased Yellow Card reporting • receive positive assessment from patients • improve the evidence base on the effectiveness of the service • support the development of outcome and/or quality measures for community pharmacy

  13. NMS – outline service spec • Patient engagement • Follows the prescribing of a new medicine for: • Asthma or COPD • Diabetes (Type 2) • Antiplatelet / Anticoagulant therapy • Hypertension • Provide patient with information on the service • Agree a method and time for the intervention (7-14 days)

  14. NMS – outline service spec • Intervention (approx. day 14) • Face to face in a consultation area or over the phone • Semi-structured interview to: • assess adherence • identify problems • identify the patient’s need for further information and support • Pharmacist provides advice and support • agree follow up / agree solution / refer to GP

  15. NMS – outline service spec • Follow up (approx. day 28) • Face to face in a consultation area or over the phone • Pharmacist provides advice and support • Patient adherent – exits the service • Patient non-adherent – refer to GP • Pharmacy record requirements and outcome data

  16. New Medicine Service • Next steps for PSNC and NHS Employers • Develop guidance for contractors and PCTs • We will work with appropriate expert stakeholders to confirm the knowledge and skills pharmacists require to deliver NMS

  17. Implementation timetable • PSNC and NHS Employers are working towards full implementation of the changes by 1st October 2011

More Related